… For the special population Phase I studies, a rich-sampling blood collection … patient on
Cycle 1 for the liver dysfunction study and on Cycle 1 and Cycle 2 for the renal impairment study. …

… phase II study was aimed at exploring the feasibility as well as clinical efficacy and tolerability
profiles of two vinflunine combinations in UC patients. … study was to determine the disease …

… patients receiving first-line treatment for metastatic breast cancer were recruited to a phase
I study of vinflunine … Results of a phase II and pharmacokinetic study in patients progressing …

… for increasing hepatic dysfunction; notably, cirrhosis or liver … Two other pharmacokinetics
trials (12 + 22 patients) were … formulations of oral vinflunine alternated with IV administration of …

… Furthermore, the incidence of renal or liver impairment, or both, in patients with cancer will
… studies or from dedicated pharmacokinetic studies done in patients with renal or hepatic …

… ); and the vinca alkaloid vinflunine as single agent or … Vinflunine: a new active drug for
second-line treatment of advanced breast cancer: results of a phase II and pharmacokinetic study …

… this study was manageable with most common grade 3/4 toxicities being neutropenia in 50%
of patients… In this phase III trial VFL did not induce a decrease in health-related quality of life …

… agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only …
hepatic dysfunction on the pharmacokinetics and safety of VFL was analyzed in a phase I study […

… In this study, 29% of mUC pts had liver metastasis, and most had prior treatment with a CPI
(79%), … Safety/tolerability and pharmacokinetics of PT2977 in this trial will also be evaluated. …

… we initiated a phase III trial comparing vinflunine with an alkylating … for locally recurrent or
metastatic breast cancer (LR/MBC). … Results of a phase II and pharmacokinetic study in patients …